View Item 

Show simple item record

FIP1L1/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis
dc.contributor.authorValent, P.en_US
dc.contributor.authorAkin, C.en_US
dc.contributor.authorMetcalfe, D. D.en_US
dc.date.accessioned2010-06-01T19:37:07Z
dc.date.available2010-06-01T19:37:07Z
dc.date.issued2007-02en_US
dc.identifier.citationValent, P.; Akin, C.; Metcalfe, D. D. (2007). "FIP1L1/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis." European Journal of Clinical Investigation 37(2): 153-154. <http://hdl.handle.net/2027.42/72754>en_US
dc.identifier.issn0014-2972en_US
dc.identifier.issn1365-2362en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72754
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17217382&dopt=citationen_US
dc.format.extent58116 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights© 2007 The Authors. Journal Compilation © 2007 Blackwell Publishing Ltden_US
dc.titleFIP1L1/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosisen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Allergy and Immunology, University of Michigan, Ann Arbor, MI, USA,en_US
dc.contributor.affiliationotherDivision of Haematology & Haemostaseology, Medical University of Vienna, Vienna, Austria,en_US
dc.contributor.affiliationotherLaboratory of Allergic Diseases, NIAID, NIH, Bethesda, MD, USAen_US
dc.identifier.pmid17217382en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72754/1/j.1365-2362.2007.01757.x.pdf
dc.identifier.doi10.1111/j.1365-2362.2007.01757.xen_US
dc.identifier.sourceEuropean Journal of Clinical Investigationen_US
dc.identifier.citedreferenceBain B, Pierre R, Imbert M, Vardiman JW, Brunning RD, Flandrin G. Chronic eosinophilic leukemia and hypereosinophilic syndrome. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization (WHO) Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001, pp. 29 – 31.en_US
dc.identifier.citedreferenceGotlib J, Cools J, Malone JM, Schrier SL, Gilliland DG, Coutre SE. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004; 103: 2879 – 91.en_US
dc.identifier.citedreferencePardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003; 102: 3093 – 6.en_US
dc.identifier.citedreferenceTravis WD, Li CY, Yam LT, Bergstralh EJ, Swee RG. Significance of systemic mast cell disease with associated hematologic disorders. Cancer 1988; 62: 965 – 72.en_US
dc.identifier.citedreferenceHorny H-P, Ruck M, Wehrmann M, Kaiserling E. Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders. Br J Haematol 1990; 76: 186 – 93.en_US
dc.identifier.citedreferenceMetcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol 1991; 96: 2S – 4S.en_US
dc.identifier.citedreferenceNagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995; 92: 10560 – 4.en_US
dc.identifier.citedreferenceSotlar K, Marafioti T, Griesser H, Theil J, Aepinus C, Jaussi R et al. Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Mol Pathol 2000; 53: 188 – 93.en_US
dc.identifier.citedreferenceValent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25: 603 – 25.en_US
dc.identifier.citedreferenceValent P, Horny H-P, Li CY, Longley JB, Metcalfe DD, Parwaresch RM et al. Mastocytosis (Mast cell disease). In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization (WHO) Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001, pp. 291 – 302.en_US
dc.identifier.citedreferenceValent P, Ghannadan M, Akin C, Krauth MT, Selzer E, Mayerhofer M et al. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts. Eur J Clin Invest 2004; 34 ( S2 ): 41 – 52.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2362.2007.01757.x.pdf
Size:
56.75KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.